Table 3.
Data at randomization for simulation 2A
| Placebo | Treatment | ASD | |
|---|---|---|---|
| n = 3000 | n = 3000 | ||
| Age (years) | 68.1 (±10.1) | 68.1 (±10.0) | 0 |
| Black race | |||
| No | 2133 (71.1%) | 2075 (69.2%) | 0.04 |
| Yes | 867 (28.9%) | 925 (30.8%) | 0.04 |
| Systolic blood pressure (mm Hg) | 140.8 (±15.1) | 140.1 (±15.1) | 0.05 |
| Diastolic blood pressure (mm Hg) | 78.1 (±11.8) | 77.7 (±11.9) | 0.04 |
| Serum creatinine (mg/dl) | 1.1 (±0.3) | 1.1 (±0.3) | 0.06 |
| Estimated GFR (ml/min/1.73 m2) | 72.2 (±19.6) | 72.0 (±20.0) | 0.01 |
| Statin use | |||
| No | 1706 (56.9%) | 1745 (58.2%) | 0.03 |
| Yes | 1294 (43.1%) | 1255 (41.8%) | 0.03 |
| Aspirin use | |||
| No | 1446 (48.2%) | 1410 (47.0%) | 0.02 |
| Yes | 1554 (51.8%) | 1590 (53.0%) | 0.02 |
| Framingham risk score | 25.2 (±12.2) | 25.2 (±11.9) | 0 |
| Smoking status | |||
| Never | 1350 (45.0%) | 1348 (44.9%) | 0 |
| Former | 1244 (41.5%) | 1220 (40.7%) | 0.02 |
| Current | 406 (13.5%) | 432 (14.4%) | 0.03 |
ASD absolute standardized difference, GFR glomerular filtration rate